Also known as: brain fog
Vaccine denial and weakened public health measures risk increasing chronic illness, as historical data shows post-infectious conditions follow major outbreaks. Long COVID affects 10-20% of those infected, while historical pandemics led to conditions like encephalitis lethargica with near 50% mortality.
Two new studies reveal long COVID's lasting biological and mental health effects. A mouse study found coronavirus triggers prolonged lung and brain damage unlike influenza, while a population study linked long COVID to significantly higher depression and anxiety risks up to three years post-infection.
Acromegaly patients face persistent symptoms including fatigue, joint pain, headaches, and brain fog despite biochemical control. Treatment burden and financial barriers remain significant, particularly in sub-Saharan Africa where diagnostic tools and therapies are often inaccessible.
A 16-year study links higher vitamin D levels in middle age to lower tau protein deposits in the brain, while a major COVID-19 trial finds vitamin D doesn't reduce acute severity but may help with long COVID recovery. Separate research shows supplementation improves vitamin D levels and stabilizes immune profiles in athletes and non-athletes.
Amylyx Pharmaceuticals is advancing avexitide toward potential FDA approval for post-bariatric hypoglycemia, with Phase 3 LUCIDITY trial results expected in Q3 2026 and a cash runway extending into 2028.
